Sjögren Syndrome Clinical Trial
Official title:
Prevalence and Characteristics of Dental and Periodontal Lesions in Patients With Sjögren's Syndrome. Establishment of a Biological Saliva Collection.
Sjögren's syndrome (SS) is a rare chronic systemic autoimmune disease characterized by destruction of the exocrine glands, including the salivary glands.The lack of saliva exposes the patient to dental caries, and dental wear although this has rarely been shown in Sjögren's patients. Moreover, these patients seem to have more inflammation and gingival recession, although this has not been clearly identified in the literature. Our main objective is to assess the prevalence of dental wear and gingival recession in patients with Sjögren's syndrome by analyzing of the Basic Erosive Wear Examination (BEWE) score for erosions, Basic Erosive Wear Abrasion (BEWA) score for attrition and percentage of sites with periodontal recessions greater than 3 mm in relation to the total number of sites. Our secondary objectives are to investigate a correlation between the prevalence of dental and gingival wear, gingival inflammation, Decayed, Missing, and Filled Teeth (DMFT) index and (1) salivary parameters and (2) oral quality of life. The salivary samples will be kept in a biological collection within the URP2496 for later analysis (biological collection CB-SJO).
Sjögren's syndrome (SS) is a rare chronic systemic autoimmune disease characterized by destruction of the exocrine glands, including the salivary glands leading to hyposiala. The lack of saliva exposes the patient to dental caries, and dental wear although this has rarely been described in Sjögren's patients. Moreover, these patients seem to have more inflammation and gingival recession, but not clinical attachment loss, although this has not been clearly identified in the literature. The present research focuses on the characterization of tooth wear and gingival recession prevalence in patients with Sjögren syndrome. A correlation of this parameters with salivary parameters (Xerostomia Inventory to assess the dryness, unstimulated salivary rate, stimulated salivary rate, pH and buffer capacity) will be assessed. The salivary samples will be kept in a biological collection within the URP2496 for later cross-sectional research purposes to identify salivary changes associated with increased risk of dental wear, dental caries, periodontal wear or periodontal inflammation (biological collection CB-SJO). This is a descriptive, prospective, open-label, non-interventional, single-center study with collection of salivary samples (CB-SJO) from a sample of patients with Sjögren's disease as part of the patient's routine care. Patients will be recruited in the oral medicine department of the AP-HP Charles Foix hospital (Ivry/seine). The time-line of the research is consistent with the usual patient management in oral medicine department. As Sjogren is a rare disease, we plan an inclusion period of 36 months. There is no specific follow-up due to the research. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02752269 -
Early Detection of Pulmonary- and Pulmonary Vascular Disease in Sjögren Syndrome
|
||
| Completed |
NCT05079581 -
Pelvic Floor Exercises in Patients With Sjögren's
|
N/A | |
| Completed |
NCT03905525 -
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
|
Phase 2 | |
| Completed |
NCT04819269 -
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
|
Phase 3 | |
| Completed |
NCT02011776 -
A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome
|
N/A | |
| Recruiting |
NCT06411132 -
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
|
||
| Completed |
NCT03762824 -
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
|
Phase 4 | |
| Terminated |
NCT04035668 -
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT02049112 -
A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study
|
Phase 4 | |
| Completed |
NCT03941184 -
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
|
||
| Completed |
NCT03608761 -
Comparison Between Rebamipide 2% Versus Autologous Serum
|
Phase 4 | |
| Active, not recruiting |
NCT04793646 -
N-acetylcysteine for Primary Sjögren's Syndrome
|
N/A |